B-type natriuretic peptide - Teva
Alternative Names: CardevaLatest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator CoGenesys
- Class
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic heart failure
Most Recent Events
- 22 Feb 2008 CoGenesys has been acquired and merged into Teva Pharmaceutical Industries